A dual-platform strategy combining engineered exosome delivery and natural exosome therapeutics.
P.S.K Biosciences is advancing exosome-based medicines through a dual-platform strategy. Our SGRL-Exo™ engineered exosome platform enables systemic, functional RNA delivery to the CNS and extrahepatic tissues. Our natural exosome therapeutics platform leverages MSC-derived exosome subpopulations (S1 and S2) for inflammation modulation, tissue regeneration, and aging-related diseases. Both platforms are built on a single-clone producer cell line architecture and a proprietary purification workflow, respectively.
Industrial-scale production, robust quality control, and a biologics-style CMC framework.
A defined single-clone architecture for reproducible exosome production, ensuring consistency across batches and scalable manufacturing.
Quality-by-design framework with critical quality attribute characterization, batch-to-batch consistency, and full documentation.
S1 and S2 natural exosome subpopulations with distinct molecular markers, validated functional activity, and indication-specific potency.
Deep dive into our engineered exosome delivery platform and our natural exosome therapeutics platform.
